Zacks Research Upgrades Mainz Biomed (NASDAQ:QUCY) to Hold

Mainz Biomed (NASDAQ:QUCY – Get Free Report) was upgraded by equities researchers at Zacks Research to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.

Several other analysts have also recently commented on QUCY. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mainz Biomed in a research report on Friday, August 7th. Wall Street Zen raised Mainz Biomed to a “hold” rating in a research report on Saturday, June 6th. Finally, Litchfield Hills Research raised Mainz Biomed to a “strong-buy” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Get Mainz Biomed alerts:

Check Out Our Latest Stock Analysis on QUCY

Mainz Biomed Stock Down 4.7%

Mainz Biomed stock opened at $1.30 on Tuesday. The business has a 50 day moving average price of $1.48. Mainz Biomed has a 52 week low of $0.30 and a 52 week high of $4.93. The firm has a market cap of $19.13 million, a price-to-earnings ratio of -0.03 and a beta of 2.31.

Key Headlines Impacting Mainz Biomed

Here are the key news stories impacting Mainz Biomed this week:

• Positive Sentiment: Litchfield Hills Research upgraded Mainz Biomed to “Strong-Buy,” providing a favorable analyst signal for the small-cap biotechnology stock. Mainz Biomed Upgraded at Litchfield Hills Research
• Positive Sentiment: Litchfield Hills forecasts improving earnings trends, with projected losses narrowing from $1.12 per share for fiscal 2026 to $0.55 in fiscal 2027 and $0.07 in fiscal 2028. The estimates suggest analysts expect progress toward breakeven, though they do not yet forecast profitability. Mainz Biomed analyst earnings estimates
• Neutral Sentiment: The analyst’s near-term estimates remain negative, including expected losses of $0.63 per share in the second quarter of 2026 and $1.12 per share for the full year, highlighting continued cash-burn and execution risk.
• Neutral Sentiment: Reported short interest was zero shares, indicating no meaningful short-selling activity in the data provided. This removes a potential source of short-covering demand but also offers little additional trading signal.

Mainz Biomed Company Profile

(Get Free Report)

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

See Also

• Five stocks we like better than Mainz Biomed
• Franco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care?
• GE Vernova’s AI Power Boom Faces a Profit Test
• Cardinal Health Earnings: Can Perfection Get Priced In Twice?
• Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand

Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.